Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Parmiani

Showing results (201-210 of 301) with videos related to

Pageof 31
Sort By:
Immunogenetics|January 1, 1993
Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1)M Vagliani, C Melani, G Parmiani, et al.
European Journal of Immunology|August 26, 1998
The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I allelesD Pende, L Accame, L Pareti, et al.
Natural Immunity and Cell Growth Regulation|January 1, 1991
Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cellsM Rodolfo, C Salvi, C Bassi, et al.
International Journal of Cancer|April 22, 1993
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5L Rivoltini, V Viggiano, S Spinazzè, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1992
Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cellsM P Colombo, L Lombardi, A Stoppacciaro, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1994
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patientsA Boiardi, A Silvani, P A Ruffini, et al.
The Journal of Experimental Medicine|April 1, 1991
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivoM P Colombo, G Ferrari, A Stoppacciaro, et al.
International Journal of Cancer|March 12, 1991
The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotypeL Rivoltini, G Cattoretti, F Arienti, et al.
Blood|March 1, 1993
Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cellsC Gambacorti-Passerini, F Grignani, F Arienti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1996
Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccinesM Rodolfo, C Zilocchi, C Melani, et al.
Pageof 31

Showing results (201-210 of 301) with videos related to

Sort By:
Pageof 31
Immunogenetics|January 1, 1993
Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1)M Vagliani, C Melani, G Parmiani, et al.
European Journal of Immunology|August 26, 1998
The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I allelesD Pende, L Accame, L Pareti, et al.
Natural Immunity and Cell Growth Regulation|January 1, 1991
Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cellsM Rodolfo, C Salvi, C Bassi, et al.
International Journal of Cancer|April 22, 1993
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5L Rivoltini, V Viggiano, S Spinazzè, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1992
Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cellsM P Colombo, L Lombardi, A Stoppacciaro, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1994
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patientsA Boiardi, A Silvani, P A Ruffini, et al.
The Journal of Experimental Medicine|April 1, 1991
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivoM P Colombo, G Ferrari, A Stoppacciaro, et al.
International Journal of Cancer|March 12, 1991
The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotypeL Rivoltini, G Cattoretti, F Arienti, et al.
Blood|March 1, 1993
Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cellsC Gambacorti-Passerini, F Grignani, F Arienti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1996
Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccinesM Rodolfo, C Zilocchi, C Melani, et al.
Pageof 31